title: Why Have So Many Intravascular Glucose Monitoring Devices Failed?
abstract: Secondary to the inherent limitations of both point-of-care and central laboratory glucose technologies, continuous glucose measurement has recently enjoyed a high level of investment. Because of the perceived advantages by some of measuring in the intravascular space compared to the subcutaneous tissue, a number of technologies have been developed. In this review, we evaluate nine systems that have shown promise, although only one of these has been cleared for sale in the United States. The detection methodology, regulatory status, technical issues, and company circumstance surrounding each technology are examined.
authors.affiliation: NIVG Consulting, Fair Play, CA, USA.
authors.forename: John L
authors.initials: JL
authors.lastname: Smith
authors.affiliation: Department of Anesthesiology, Vanderbilt University Medical Center, Nashville, TN, USA mark.j.rice@vanderbilt.edu.
authors.forename: Mark J
authors.initials: MJ
authors.lastname: Rice
mesh_terms: D001786:Blood Glucose / Q000032:analysis*; D018795:Device Approval; D004867:Equipment Design; D005336:Fiber Optic Technology; D006801:Humans; D015918:Infusion Pumps, Implantable; D008991:Monitoring, Physiologic / Q000295:instrumentation* / Q000379:methods; D061214:Patient Safety; D019095:Point-of-Care Systems; D015203:Reproducibility of Results; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D001786:Blood Glucose
keywords: FDA approval; continuous glucose monitoring; intravascular monitoring